Drug development company, Aelix Therapeutics, has appointed HIV expert, Dr Ian McGowan, as chief medical officer (CMO).
McGowan previously served as a principal investigator of the Microbicide Trials Network (MTN), which focuses on developing topical products for the prevention of HIV infection. Currently, he leads the rectal microbicide programme at MTN.
“We are delighted Dr McGowan has joined our company as CMO,” said Dr Christian Brander, chief scientific officer and co-founder of Aelix Therapeutics. “We have been working with him as a consultant since 2016. We believe that his extensive knowledge in the antiviral field, especially in antiretroviral drug development, combined with his regulatory experience and large network will help us further our research on the HTI immunogen.”
“Research into novel cure/eradication strategies for HIV infection is gathering significant momentum. I believe that the HTI immunogen has great potential to be a pivotal component in these strategies,” said McGowan. “I am delighted to be able to contribute to the work in advancing the HTI immunogen towards the clinical proof-of-concept stage.”